share_log

榮昌生物:截至二零二四年四月三十日止月份之股份發行人的證券變動月報表

REMEGEN: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2024

Hong Kong Stock Exchange ·  May 7 04:30
Summary by Moomoo AI
榮昌生物製藥(煙台)股份有限公司於2024年5月7日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年4月30日的股份變動情況。報告顯示,公司的H類普通股股份數目在4月份未有變動,結存為189,581,239股,每股面值1人民幣。A類普通股亦未見增減,結存維持在354,750,844股。此外,報告提及了2022年及2023年的A股股票激勵計劃,但在4月份並無新股份發行。公司確認所有證券發行均獲董事會批准,並符合相關法律規定。
榮昌生物製藥(煙台)股份有限公司於2024年5月7日向香港交易及結算所有限公司提交了最新的證券變動月報表,報告截至2024年4月30日的股份變動情況。報告顯示,公司的H類普通股股份數目在4月份未有變動,結存為189,581,239股,每股面值1人民幣。A類普通股亦未見增減,結存維持在354,750,844股。此外,報告提及了2022年及2023年的A股股票激勵計劃,但在4月份並無新股份發行。公司確認所有證券發行均獲董事會批准,並符合相關法律規定。
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. filed with Hong Kong Trading and Settlement Limited on May 7, 2024 its latest Securities Changes Monthly Report, reporting stock changes for the year ended April 30, 2024. The report showed that the company's number of Class H ordinary shares remained unchanged in April, amounting to 189,581,239 shares with a face value of RMB 1 per share. Class A ordinary shares also showed no increase and cash balances remained at 354,750,844 shares. In addition, the report mentioned the A-share incentive plan for 2022 and 2023, but no new shares were issued in April. The Company confirms that all securities issuances are approved by the Board of Directors and comply with relevant legal requirements.
Wing Cheong Biopharmaceuticals (Yantai) Co., Ltd. filed with Hong Kong Trading and Settlement Limited on May 7, 2024 its latest Securities Changes Monthly Report, reporting stock changes for the year ended April 30, 2024. The report showed that the company's number of Class H ordinary shares remained unchanged in April, amounting to 189,581,239 shares with a face value of RMB 1 per share. Class A ordinary shares also showed no increase and cash balances remained at 354,750,844 shares. In addition, the report mentioned the A-share incentive plan for 2022 and 2023, but no new shares were issued in April. The Company confirms that all securities issuances are approved by the Board of Directors and comply with relevant legal requirements.
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more